Quest Diagnostics buys cancer test
This article was originally published in The Gray Sheet
Firm gains InSure fecal immunochemical colorectal cancer screening test, as well as the InSure II version of the test, cleared by FDA in May for use in doctors' offices, via its $45 mil. purchase of privately held Australian company Enterix. The deal, announced Sept. 7, follows Quest's acquisition of HerpeSelect herpes virus test manufacturer Focus Diagnostics for $185 mil. in July. For the second quarter, Quest reported revenue of $1.6 bil., up 15% from the prior-year period...
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.